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CONDENSATION: These Phase 3 studies demonstrated efficacy and safety of 
Astodrimer 1% Gel for treatment of bacterial vaginosis (BV). 














Astodrimer is a dendrimer formulated in a vaginal gel to treat bacterial vaginosis (BV) 
and prevent recurrence. The objective of these studies was to confirm the efficacy and 
safety of Astodrimer 1% Gel for treatment of BV. 
Study Design: 
Women with bacterial vaginosis were randomized 1:1 to Astodrimer 1% Gel (Study 1 
conducted in the United States, N=127; Study 2 conducted in the United States, 
Germany and Belgium, N=128) or placebo gel (Study 1, N=123; Study 2, N=123) at a 
dose of 5 g vaginally once daily for 7 days. The primary endpoint was clinical cure, 
defined as i) absence of bacterial vaginosis vaginal discharge; ii) <20% clue cells; and 
iii) negative whiff test at day 9-12. Secondary efficacy analyses included clinical cure at 
day 21-30. Other endpoints at days 9-12 and 21-30 included Nugent cure (Nugent score 
≤3), absence of symptoms, and adverse events. The primary analysis in the modified 
intent-to-treat population used the Cochran Mantel Haenszel test stratified by analysis 
center with a two-sided significance level of α=.05. 
Results: 
Astodrimer 1% Gel was superior to placebo for the primary and selected secondary 
efficacy measures. Clinical cure rates at day 9-12 were 50.4% (59/117) vs 16.5% 
(19/115, P<.001) (Study 1) and 56.7% (68/120) vs 21.4% (25/117, P<.001) (Study 2) for 











difference to placebo was not statistically significant. Nugent cure rates at day 9-12 
were 12.8% (15/117) vs 2.6% (3/115, P=.004) (Study 1) and 13.3% (16/120) vs 5.1% 
(6/117, P=.030) (Study 2) for astodrimer vs placebo. A greater proportion of women 
receiving astodrimer reported absence of vaginal discharge and absence of vaginal 
odor at day 9-12 and day 21-30 compared with placebo. Adverse events were generally 
mild and self-limiting. For the combined studies, adverse events potentially related to 
treatment occurred in 14.7% (37/252) of astodrimer patients vs 9.4% (23/244) for 
placebo, including vulvovaginal candidiasis reported for 2.4% (6/252) of astodrimer 
patients. 
Conclusion: 
These results support a role for Astodrimer 1% Gel as an effective, safe and well-
tolerated treatment for women with bacterial vaginosis. 
 













Bacterial vaginosis (BV) is a syndromic condition resulting from a heterogeneous 
dysbiosis. 1 The adverse impact of BV symptoms of vaginal odor and discharge on 
women’s social experiences and broader quality of life is significant. 2 Clinical 
management of BV focuses on treatment of symptoms and follow-up typically only 
occurs if patients do not get relief from symptoms or relapse.3,4 
Conventional antibiotics are not well tolerated by patients due to gastrointestinal side 
effects, interaction with alcohol and high rates of vulvovaginal candidiasis. Relapse of 
BV after treatment is common. Current treatment options are inadequate to sufficiently 
address the condition, and alternate therapies are required.5,6,7,8 
Astodrimer is a dendrimer molecule and has been shown to inhibit growth of several 
organisms implicated in the pathogenesis of BV, including Gardnerella vaginalis and 
Prevotella bivia. Astodrimer blocks bacterial attachment, and disrupts and prevents 
formation of bacterial biofilms, so that potential for development of resistance is low. It is 
not systemically absorbed, helping avoid potential systemic side effects common to 
antibiotics.9,10 
The efficacy of Astodrimer 1% Gel for treatment of BV was initially demonstrated in a 
Phase 2 study of similar design to the current studies, in which the product was superior 
to placebo by all efficacy measures.11 The current studies aimed to confirm the utility of 











MATERIALS AND METHODS: 
Study Design 
These were two Phase 3, double-blind, multicenter, randomized, placebo-controlled 
studies (Study 1 and Study 2) to confirm the efficacy and safety of Astodrimer 1% Gel 
compared with placebo (hydroxyethyl cellulose placebo gel)12,13, in women with BV. 
The studies complied with the Declaration of Helsinki, Good Clinical Practice, regulatory 
guidelines and relevant local legislation, and were approved by an institutional review 
board on 24 February 2012 (Quorum Review, Inc.). The studies were registered on 
clinicaltrials.gov on 12 April 2012 (NCT01577238 and NCT01577537). 
All patients provided written informed consent and were screened for eligibility at the 
baseline visit (study day 1). 
Eligible women were randomized in a 1:1 ratio using a computer-generated 
randomization list to Astodrimer 1% Gel or placebo gel, which were colorless gels 
packaged in identical, pre-filled, vaginal applicators, each containing a single dose (5g).  
Women self-administered a dose vaginally once daily for 7 days and then attended an 
end of treatment (EOT) visit between study days 9-12. A 2-3 week follow-up period 
concluded with a visit between study days 21-30. Both care providers and patients were 
unaware of treatment allocations throughout the study. Patients could withdraw from the 











Women who reported no improvement in BV symptoms, or who relapsed between EOT 
and the follow-up visit, could request rescue medication, provided the investigator 
confirmed the presence of BV. Women who received rescue medication were 
considered failures with respect to clinical cure and were assessed for safety up to the 
final study visit (days 21-30). 
At each visit, women had a pelvic/gynecological examination, adverse events (AEs) 
were recorded, BV symptoms were reviewed, and protocol adherence was assessed. 
Women completed diary cards to capture data on symptoms, sexual activity, 
menstruation, and AEs. 
Study Population 
Post-menarchal women aged 12 years or older, with a diagnosis of BV defined as 
presence of 4 Amsel criteria (discharge; vaginal fluid pH >4.5; ≥20% clue cells; and 
positive 10% potassium hydroxide whiff test) 14 and Nugent score (NS) ≥415 were 
eligible. The protocol allowed enrolment before confirmation of a NS ≥4 if an OSOM® 
BV Blue® test (Sekisui Diagnostics; Burlington MA, USA) returned a positive result. 
Women who were pregnant, planning to become pregnant, lactating, or within 3 months 
of last pregnancy outcome at enrolment, and women testing positive for urinary tract 
infection, or who had signs/symptoms of active genital herpes simplex virus or other 
sexually transmitted infection (STI) at screening were excluded from participation. 
Women who had received antifungal or antimicrobial therapy (systemic or intravaginal) 











gonorrhoeae and Trichomonas vaginalis testing was conducted at screening but results 
were unavailable at the time of randomization. 
Concomitant vaginal or systemic antibiotic and vaginal antifungal therapies were 
prohibited during the study and use of other vaginally administered products was 
discouraged. 
Outcomes 
The primary efficacy endpoint was clinical cure defined as normal physiological 
discharge, whiff test negative for amine odor, and <20% clue cells. 
At the time of study conduct, the US Food and Drug Administration (FDA) required the 
assessment at study days 21-30 be the primary endpoint in accordance with its 1998 
guidance on BV. In 2016, FDA re-issued its guidance on BV recommending the primary 
assessment of cure be at study days 7-14. This timing is consistent with study days 
7-10 for assessment of treatment success proposed by a US National Institutes of 
Health workshop on BV clinical practice16, and with the timing of the key, pre-specified 
endpoint at day 9-12 used in the current studies. 
For this reason, the original primary endpoint at day 21-30 was changed to day 9-12 
and clinical cure at day 21-30 became a secondary endpoint. 
Other secondary efficacy measures assessed at day 9-12 and the follow-up visit 
included Nugent cure (NS ≤3), and absence of vaginal discharge and vaginal odor 











Additional assessments included resolution of each individual Amsel criterion, NS and 
use of rescue medication. 
Clinical cure was also assessed for population subgroups including baseline NS, 
condom use during the studies, number of previous episodes of BV in the past 
12 months, use of vaginal products during the studies, menses occurring during the 
studies, and by geographic region (Study 2 only). 
AEs were monitored throughout the studies. 
Statistical Analyses 
Primary and secondary efficacy analyses using the Cochran-Mantel-Haenszel test 
controlling for study center were performed on the modified intent-to-treat (mITT) 
population, which was all patients randomized who had administered ≥1 dose of study 
product and had a NS ≥4 at the baseline visit. Missing data were imputed as failure.  
The safety population was all patients randomized who received ≥1 dose of study 
product. 
Sensitivity analyses (last-observation-carried-forward [LOCF] and “as observed”) were 
applied to participants who received rescue medication, with the last observation prior to 
rescue medication being carried forward. Absence of symptoms at day 9-12 and follow-










Sample Size Calculation 
Assuming clinical cure rates of 30% and 12% for Astodrimer 1% Gel and placebo, 
respectively, a sample size of 212 evaluable participants provided 90% power to detect 
a treatment difference with a significance level of α=.05 (2-sided). Assuming a 12% 
attrition rate, 120 subjects per treatment arm and 240 subjects overall in each study 












Disposition and Demographics 
Between March and July 2012, a total of 250 women were randomized to Astodrimer 
1% Gel (astodrimer) (N=127, 50.8%) or placebo (N=123, 49.2%) at 17 US sites in Study 
1. In Study 2, 251 women were randomized to astodrimer (N=128, 51.0%) or placebo 
(N=123, 49.0%) between April and October 2012 at 11 centers in the US, 3 in Belgium 
and 3 in Germany. The mITT population included 232 women in Study 1 and 237 
women in Study 2. Treatment groups were well-balanced with respect to demographic 
and baseline characteristics, with the exception that the proportion of patients with 
Nugent score 7 to 10 at baseline was lower in the placebo group compared with 
astodrimer in Study 2 (Table 1). The majority of women completed the study (Figure 1). 
Efficacy 
Astodrimer was superior to placebo for the primary outcome measure at day 9-12. In 
Study 1, 50.4% (59/117) of women given astodrimer achieved clinical cure compared to 
16.5% (19/115) for placebo (P<.001); in Study 2, clinical cure rates were 56.7% 
(68/120) vs 21.4% (25/117), respectively (P<.001) (Table 2). 
The proportions of patients with resolution of individual Amsel criteria, including pH, 
were statistically significantly higher for astodrimer patients vs placebo at day 9-12 in 
both Study 1 (data not shown) and Study 2 (Figure 2). 
Resolution of BV symptoms at day 9-12 was also superior for women given astodrimer 











more than 50% of women were odor-free within 1 day of the first astodrimer dose 
(Figure 3). 
Nugent cure proportions at day 9-12 were 12.8% (15/117) vs 2.6% (3/115, P=.004) 
(Study 1) and 13.3% (16/120) vs 5.1% (6/117, P=.030) (Study 2) for astodrimer vs 
placebo. A majority of the participants in the astodrimer groups (61.1% [58/95] and 
63.7% [72/113]) had a NS in the 0-6 range at day 9-12, compared with 7.5% (8/107) 
and 14.2% (15/106) for placebo (P<.001).  
Differences between groups narrowed at the follow-up visit but still favored astodrimer, 
and were in some cases statistically significant. Clinical cure proportions at the follow-up 
visit were 28.2% (31/117) and 30.8% (37/120) for astodrimer (Study 1 and 2, 
respectively) compared with 20.9% (24/115) and 28.2% (33/117) for placebo (P>.05). 
Vaginal discharge and vaginal odor were absent at follow-up (day 21-30) for a majority 
of women in the astodrimer group (Discharge: 61/117 [52.1%] and 72/120 [60.0%] in 
Study 1 and 2, respectively; Odor: 61/117 [52.1%] and 76/120 [63.3%]) compared with 
placebo (Discharge: 43/115 [37.4%], P=0.023 and 59/117 [50.4%], P=0.131; Odor: 
51/115 [44.3%], P=0.222 and 54/117 [37.4%], P=0.006).  
Slightly fewer women receiving astodrimer (53/117 [45.3%] and 58/120 women [48.3%] 
in Study 1 and 2, respectively) used rescue medication (typically metronidazole 0.75% 
vaginal gel) compared with placebo (59/115 [51.3%] and 67/117 [57.3%] women). Of 
these, most received the rescue medication at the follow-up visit. 











subgroup of patients with baseline NS ≥7, astodrimer was also superior to placebo: 
52.7% (58/110) vs 17.3% (19/110); and 57.5% (65/113) vs 14% (14/100) in Study 1 and 
2, respectively; both P<.001. The treatment effect in this subgroup was greater than the 
effect in the subgroup of patients with baseline NS <7 in Study 2 (P<.002). There was 
no difference in treatment effect in either study for any other subgroups assessed. 
Based on diary data for both studies combined, a somewhat higher proportion of 
women reported penile-vaginal intercourse and unprotected sex in the astodrimer group 
(59.1% and 29.8%, respectively) than placebo (53.0% and 26.0%) between EOT and 
follow-up. Menstrual bleeding and tampon use were also more frequent in the 
astodrimer group (47.4% and 25.2%) compared to the placebo group (43.6% and 
17.2%) between EOT and follow-up. 
Safety/tolerability 
The overall incidence of AEs in the combined safety population was 41.4% (101/244) 
for placebo and 42.9% (108/252) for astodrimer (Table 3). AEs potentially related to 
treatment occurred in 9.4% (23/244) of placebo patients vs 14.7% (37/252) for 
astodrimer.  
Vulvovaginal candidiasis, regardless of relationship to treatment, was reported in 15 
(6.0%) and 9 (3.7%) women in the astodrimer and placebo groups, respectively. 
Vulvovaginal candidiasis considered potentially related to study treatment was reported 
in 6/252 (2.4%) of patients using astodrimer vs 0/244 (0%) in placebo. 











astodrimer discontinued treatment and the study due to a case of vaginal hemorrhage 
that was of moderate intensity and deemed unrelated to study treatment. One serious 
AE (pneumonia on day 27 requiring hospitalization) for a participant given astodrimer 












Astodrimer is a novel dendrimer administered vaginally and is not systemically 
absorbed.8,9 Unpublished data show that it is able to inhibit formation of and disrupt 
biofilms, likely due to its ability to block bacterial adhesion. Therefore, astodrimer avoids 
issues typically associated with conventional antibiotics, such as systemic side effects 
and antibiotic resistance, and overgrowth of Candida species following treatment is 
minimal. 
In these studies, clinical cure rates for astodrimer at day 9-12 (50-59%) were 
comparable to cure rates reported for conventional antibiotic products such as 
secnidazole using comparable cure criteria at a similar timeframe (58%).17 
The absence of symptoms observed at day 9-12 and at follow-up is of particular 
importance for the routine clinical management of BV since patients will only return to 
the clinic if their symptoms persist or recur. Speed of resolution of BV symptoms is also 
important, because of the negative impact of BV symptoms on overall quality of life, 
relationships, and ability to work. 2 While >50% of women had absence of vaginal odor 
within 1 day of first astodrimer dose, a study of metronidazole 0.75% gel showed 
median time to resolution of vaginal odor of 3 days. 18 
Differences between astodrimer and placebo were in most cases no longer statistically 
significant at the follow-up visit, although women given astodrimer still showed a slightly 
better response than those given placebo across most efficacy endpoints. 











rate at the follow-up timepoint was 28.8%17, which is similar to the cure rates observed 
at a similar time in our current studies. In that same study, the percentage of patients 
without relapse of symptoms at the day 21-30 study visit was approximately 22%, which 
is approximately half the percentage seen with astodrimer. 
BV shares some characteristics with STIs19, whereby re-exposure to triggers of BV, 
such as unprotected sex, douching or menses, may result in re-infection or relapse. In 
the current studies, there was a trend showing a somewhat higher proportion of women 
given astodrimer compared with placebo engaged in unprotected sex or had menses 
between the day 9-12 and follow-up visits, potentially increasing the likelihood of BV 
recurrence in this treatment group. This finding, along with unexpectedly high and 
improving cure rates for placebo between EOT and follow-up, may have led to 
narrowing of the differences in response between astodrimer and placebo, and the need 
for rescue medication at follow-up, which was similar between treatment groups.  
Most episodes of candidiasis occurred during follow-up, which is expected after 
treatment of BV, but did not require treatment. The low incidence of candidiasis 
following treatment with astodrimer contrasts favorably with the frequency for 
conventional antibiotic therapies, such as single dose oral secnidazole (13.6% vs 4.7% 
in placebo).16 
Despite the narrowing of response and similar level of use of rescue therapy at follow-
up in this study, the non-antibiotic mechanism and well-tolerated safety profile of 
Astodrimer Gel means that the product may be better-suited than standard antibiotic 











cases where that is required. Studies have shown continuing use of the product is able 
to prevent recurrence of BV.20  
Strengths and limitations 
Strengths of the studies were that they were both well-controlled, double-blind, 
multicenter, placebo-controlled, and randomized Phase 3 studies. The studies were 
adequately powered to detect a difference in BV cure rates between astodrimer and 
placebo. 
A limitation is that the analysis of efficacy at day 9-12 was not the pre-specified primary 
endpoint of the studies. However, the risk of type I error in interpreting these results is 
minimized because assessment at day 9-12 was the sponsor’s preferred primary 
endpoint when designing the studies and was a key, pre-specified secondary endpoint. 
In addition, the change in presentation was only made after the FDA published revised 
guidance on BV in 2016. In addition, the clinical response at day 9-12 was consistent 
across these two Phase 3 studies as well as the Phase 2 study10, with substantially 
homogenous relative risks of cure that consistently favored astodrimer vs placebo (i.e., 
P values consistently <.001). 
Conclusions 
Astodrimer is a novel therapy, which acts locally, is not systemically absorbed and has a 
non-antibiotic mechanism of action related to effects on biofilms, thereby avoiding 
potential issues associated with conventional antibiotics.  











effective and well-tolerated for the treatment of women with BV, including relief of 
symptoms. Astodrimer has potential to fulfil areas of unmet clinical need in treatment of 
BV, such as women who fail to respond to or are intolerant of existing antibiotic 
therapies for BV, or who want an alternate treatment modality. 
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Table 1: Baseline Characteristics (modified intent-to-treat population), by 
treatment group 









Age (yr)     
Mean (SD) 32.3 (10.0) 32.9 (9.7) 34.9 (9.9) 36.2 (12.3) 
Range 18 to 57 18 to 57 18 to 59 19 to 88 
Race, n (%)     
White 48 (41.0) 40 (34.8) 62 (51.7) 60 (51.3) 
Black 62 (53.0) 68 (59.1) 54 (45.0) 51 (43.6) 
All Othersa 7 (6.0) 7 (6.1) 4 (3.3) 6 (5.1) 
Nugent Score, n (%)     
4 to 6 7 (6.0) 5 (4.3) 7 (5.8) 17 (14.5) 
7 to 10 110 (94.0) 110 (95.7) 113 (94.2) 100 (85.5) 
N=number of patients; n=number of patients with observation; yr =years;  
SD=standard deviation  
a All Others=Native American or Alaskan Native, Native Hawaiian or Other Pacific 
Islander, Middle Eastern, Multiple (i.e., White/African-American, White/African-













Table 2: Efficacy outcomes at end of treatment (study days 9 to 12) (modified intent-to-treat population), by study 
and treatment group 
Endpoint 
Astodrimer Placebo 
RR (95% CI) P value 
n/N (%) [95% CI] n/N (%) [95% CI] 
Study 1 
Clinical Curea 59/117 (50.4) [41.0, 59.8] 19/115 (16.5) [10.3, 24.6] 3.05 (1.95, 4.78) <.001b 
Clinical Curec 59/105 (56.2) [46.2, 65.9] 19/108 (17.6) [10.9, 26.1] 3.19 (2.05, 4.97) <.001b 
Absence of Dischargec 67/106 (63.2) [53.3, 72.4] 49/110 (44.5) [35.1, 54.3] 1.42 (1.10, 1.83) .010b 
Absence of Odorc 83/106 (78.3) [69.2, 85.7] 51/110 (46.4) [36.8, 56.1] 1.69 (1.35, 2.11) <.001b 
Study 2 
Clinical Curea 68/120 (56.7) [47.3, 65.7] 25/117 (21.4) [14.3, 29.9] 2.65 (1.81, 3.88) <.001b 
Clinical Curec 68/116 (58.6) [49.1, 67.7] 25/111 (22.5) [15.1, 31.4] 2.60 (1.78, 3.80) <.001b 
Absence of Dischargec 88/117 (75.2) [66.4, 82.7] 51/109 (46.8) [37.2, 56.6] 1.61 (1.28, 2.01) <.001b 
Absence of Odorc 96/117 (82.1) [73.9, 88.5] 49/109 (45.0) [35.4, 54.8] 1.83 (1.46, 2.28) <.001b 
N=number of patients; n=number of patients with observation; CI=confidence interval; RR=relative risk (of event) 
a Missing values imputed as failures 
b Indicates statistical significance 












Table 3: Tolerability (safety population: Study 1 and 2 combined), by 
treatment group 







Patients with ≥1 AE 108 (42.9) 101 (41.4) 
Patients with ≥1 AE considered by 
investigator to be related to study treatment 
37 (14.7) 23 (9.4) 
Patients with ≥1 severe AE 1 (0.4) 5 (2.0) 
Patients with ≥1 serious AE 1 (0.4) 0 
Patients who stopped treatment due to AE 1 (0.4) 0 
AE of special interest   
Urinary Tract Infection 4 (1.6) 3 (1.2) 
Vulvovaginal Candidiasis 15 (6.0) 9 (3.7) 
AEs (incidence ≥5%)   
Headache 19 (7.5) 17 (7.0) 
Vulvovaginal Candidiasis 15 (6.0) 9 (3.7) 
Vulvovaginal Pruritus 13 (5.2) 11 (4.5) 
AEs considered by investigator to be related 
to study treatment (incidence ≥2%) 
  
Vulvovaginal Pruritus 9 (3.6) 5 (2.1) 
Vulvovaginal Burning Sensation 6 (2.4) 2 (0.8) 
Vulvovaginal Candidiasis 6 (2.4) 0 (0) 
Vulvovaginal Discomfort 1 (0.4) 6 (2.5) 













Figure 1: CONSORT diagram 
Figure 1 Description: Study 1 and Study 2 CONSORT diagrams 
 
 
Figure 2: Proportion of patients with resolution of Amsel criteria at day 9-12 for 
Astodrimer 1% Gel or placebo – Study 2 
Figure 2 Description: Proportion of patients with resolution of individual Amsel 
criteria at day 9-12 for Astodrimer 1% Gel or placebo, by treatment group in 













Figure 3: Proportion of patients odor-free by day after first dose of Astodrimer 1% 
Gel or placebo 












Astodrimer 1% Gel or placebo, by treatment group (Study 1 Astodrimer 1% Gel: 
N=116; Study 2 Astodrimer 1% Gel: N=122; Study 1 Placebo: N=112; Study 2 
Placebo: N=117) 
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